{
    "clinical_study": {
        "@rank": "80667", 
        "arm_group": [
            {
                "arm_group_label": "Quilizumab", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This multicenter, randomized, double-blind, placebo-controlled, parallel-group s tudy will\n      assess the efficacy and safety of additional quilizumab therapy in adu lt patients with\n      Chronic Spontaneous Urticaria resistant to antihistamine treatm ent."
        }, 
        "brief_title": "A Study of Quilizumab Versus Placebo in Patients With Refractory Chronic Spontaneous Urticaria", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Urticaria", 
        "condition_browse": {
            "mesh_term": "Urticaria"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of CSU refractory to H1 antihistamines with/without LTRAs, as defined by\n             the following:\n\n          -  The presence of itch and hives for > 6 consecutive weeks at any time prior to\n             enrollment despite use of H1 antihistamines during this time period\n\n          -  UAS7 score greater than 16 and itch component of UAS7 greater than 8 during 7 days\n             prior to Day 1. Patients must have been on daily stable doses of H1 antihistamine for\n             at least 3 consecutive days immediately prior to the screening visit and must\n             document current use at screening\n\n          -  CSU diagnosed for more than 6 months\n\n          -  Patients must have a minimum diary compliance (6 out of 7 consecutive days) prior to\n             Day 1\n\n        Exclusion Criteria:\n\n          -  Treatment with an investigational agent within 30 days of screening, and previous\n             treatment with monoclonal antibody therapies used to treat CSU 9 months prior to\n             screening\n\n          -  Chronic urticarias other than CSU, including the following: Acute, solar,\n             cholinergic, heat, cold, aquagenic, delayed pressure or contact.\n\n          -  Other diseases and conditions with symptoms of urticaria.\n\n          -  Routine doses of the following medications within 30 days prior to screening:\n             systemic or topical corticosteroids (prescription or over the counter),\n             hydroxychloroquine, methotrexate, cyclosporine, or cyclophosphamide\n\n          -  IV immunoglobulin G (IVIG), or plasmapheresis within 30 days prior to screening\n\n          -  Patients with cancer, history of cancer considered uncured or in complete remission\n             for < 10 years, or currently under work-up for suspected cancer except non-melanoma\n             skin cancer that has been treated or excised and is considered resolved\n\n          -  History of anaphylactic shock without clearly identifiable avoidable antigen\n\n          -  Presence of clinically significant cardiovascular, neurological, psychiatric,\n             metabolic or other pathological conditions.\n\n          -  Medical examination or laboratory findings that suggest the possibility of\n             decompensation of co-existing conditions for the duration of the study.\n\n          -  Evidence of current drug or alcohol abuse\n\n          -  Nursing women and women of childbearing potential, unless using effective\n             contraception as defined by protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01987947", 
            "org_study_id": "GX29107"
        }, 
        "intervention": [
            {
                "arm_group_label": "Quilizumab", 
                "description": "Two administrations by subcutaneous injection", 
                "intervention_name": "Quilizumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Two administrations by subcutaneous injection", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "MEMP1972A", 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M4V 1R2"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "10117"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mainz", 
                        "country": "Germany", 
                        "zip": "55131"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Canada", 
                "Germany"
            ]
        }, 
        "number_of_arms": "2", 
        "overall_official": {
            "affiliation": "Genentech", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Efficacy: Absolute change from baseline to Week 20 in the weekly itch score.", 
                "safety_issue": "No", 
                "time_frame": "21 weeks"
            }, 
            {
                "measure": "Safety: Incidence & severity of adverse events.", 
                "safety_issue": "No", 
                "time_frame": "Approximately 30 weeks"
            }, 
            {
                "measure": "Safety: Incidence of anti-therapeutic antibodies.", 
                "safety_issue": "No", 
                "time_frame": "Approximately 30 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01987947"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Efficacy: Absolute change from baseline to Week 4 in the weekly itch score.", 
                "safety_issue": "No", 
                "time_frame": "5 weeks"
            }, 
            {
                "measure": "Efficacy: Absolute change from baseline to Week 20 in the UAS7 aggregate score.", 
                "safety_issue": "No", 
                "time_frame": "21 weeks"
            }
        ], 
        "source": "Genentech", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}